Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px
Document › Details

Agilent Technologies Inc.. (1/31/17). "Press Release: Agilent Technologies Expands Dako’s CE Marked PD-L1 IHC 22C3 pharmDx Companion Diagnostics". Carpinteria, CA.

Region Region Europe
Product Product PD-L1 IHC 22-C3 pharmDx (Dako)
Persons Person Thaysen, Jacob (Agilent 201411 VP + President of DGG business unit joined Agilent via acquisition of Dako)
  Person 2 Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)
     


Patients with PD-L1-positive unresectable, advanced or recurrent NSCLC can now be identified for treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx.


Agilent Technologies Inc. (NYSE: A) today announced that its CE marked Dako PD-L1 IHC 22C3 pharmDx can now be used to determine PD-L1 expression status to inform the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy manufactured by Merck (known as MSD outside the U.S. and Canada). This intended use allows PD-L1 IHC 22C3 pharmDx to detect PD-L1 expression in both untreated and previously treated metastatic NSCLC patients.

KEYTRUDA is now approved for the first-line treatment of metastatic NSCLC patients whose tumors express high levels of PD-L1 (tumor proportion score of 50 percent or more) or for previously treated metastatic NSCLC patients whose tumors express PD-L1 (tumor proportion score of 1 percent or more).

This update of PD-L1 IHC 22C3 pharmDx means that the assay can be used to identify previously untreated patients with metastatic NSCLC expressing high levels of PD-L1 for treatment with KEYTRUDA. Prior to this, chemotherapy was the standard first-line treatment for most NSCLC patients. Patients in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA using PD-L1 IHC 22C3 pharmDx.

PD-L1 IHC 22C3 pharmDx is the only assay shown to select NSCLC patients with benefit from first-line treatment with anti-PD-1 monotherapy.

"We are so pleased that first-line metastatic NSCLC patients in Europe will now be included in the expansion of the intended use of PD-L1 IHC 22C3 pharmDx. With PD-L1 IHC 22C3 pharmDx, European pathologists have the ability to accurately identify the PD-L1 expression of a patient's tumor, which ultimately enables the oncologist to provide the best treatment for that particular patient" said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "Pathologists recognize the need for validated tests, and our companion diagnostic gives them a highly accurate tool to inform oncologists on PD-L1 expression."

"KEYTRUDA data continues to demonstrate the important role of PD-L1 testing in the treatment of patients with non-small cell lung cancer in order to identify those patients most likely to respond to treatment," said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. "The expansion of the companion diagnostic's approval to include first-line evaluation means European oncologists have the ability to help even more patients with lung cancer."

Lung cancer is the leading cause of cancer-related death worldwide, and NSCLC accounts for 80 percent of all lung cancers.

PD-L1 IHC 22C3 pharmDx was developed in partnership with Merck & Co., Inc., Kenilworth, NJ, USA, maker of the anti-PD-1 therapy KEYTRUDA.

KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.20 billion in fiscal 2016. The company employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

# # #

Contact:

Victoria Wadsworth-Hansen
Agilent Technologies
+1 408-553-2005
+45 29336980
victoria.wadsworth-hansen@agilent.com

   
Record changed: 2017-02-08

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px